Average arterial oxyhemoglobin saturation during sleep (AvSpO 2 S) is a clinically relevant measure of physiological stress associated with sleep-disordered breathing, and this measure predicts incident cardiovascular disease and mortality. Using high-depth wholegenome sequencing data from the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine (TOPMed) project and focusing on genes with linkage evidence on chromosome 8p23, 1,2 we observed that six coding and 51 noncoding variants in a gene that encodes the GTPase-activating protein (DLC1) are significantly associated with AvSpO 2 S and replicated in independent subjects. The combined DLC1 association evidence of discovery and replication cohorts reaches genome-wide significance in European Americans (p ¼ 7.9 3 10 À7 ). A risk score for these variants, built on an independent dataset, explains 0.97% of the AvSpO 2 S variation and contributes to the linkage evidence. The 51 noncoding variants are enriched in regulatory features in a human lung fibroblast cell line and contribute to DLC1 expression variation. Mendelian randomization analysis using these variants indicates a significant causal effect of DLC1 expression in fibroblasts on AvSpO 2 S. Multiple sources of information, including genetic variants, gene expression, and methylation, consistently suggest that DLC1 is a gene associated with AvSpO 2 S.Arterial oxyhemoglobin saturation (SpO 2 ) reflects the adequacy of ventilation and oxygen transport, fundamental physiological properties that are tightly regulated at molecular and cellular levels to ensure delivery of oxygen to vital tissues. Reductions in oxyhemoglobin saturation lead to increased rates of mortality and cognitive decline. 3 Given its clinical relevance, oxygen saturation is commonly monitored in patients with pulmonary, cardiac, and sleep